These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 37244385)

  • 21. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expansion of Opportunistic Enteric Fungal Pathogens and Occurrence of Gut Inflammation in Human Liver Echinococcosis.
    Wang Y; Guo A; Liu Z; Zou Y; Zhu W; Wu S; Zhang S; Guo X; Zhang S; Pu L; Zhu XQ; Zhu G; Cai X; Wang S
    Microbiol Spectr; 2022 Oct; 10(5):e0145322. PubMed ID: 36098525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Fungal Mycobiome and Its Interaction with Gut Bacteria in the Host.
    Sam QH; Chang MW; Chai LY
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28165395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut microbial metabolites in obesity, NAFLD and T2DM.
    Canfora EE; Meex RCR; Venema K; Blaak EE
    Nat Rev Endocrinol; 2019 May; 15(5):261-273. PubMed ID: 30670819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The human gut mycobiome and the specific role of Candida albicans: where do we stand, as clinicians?
    Musumeci S; Coen M; Leidi A; Schrenzel J
    Clin Microbiol Infect; 2022 Jan; 28(1):58-63. PubMed ID: 34363944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in the type 2 diabetes gut mycobiome associate with metformin treatment across populations.
    Van Syoc E; Nixon MP; Silverman JD; Luo Y; Gonzalez FJ; Elbere I; Klovins J; Patterson AD; Rogers CJ; Ganda E
    mBio; 2024 Jun; 15(6):e0016924. PubMed ID: 38767350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the gut microbiome and its metabolites in metabolic diseases.
    Wu J; Wang K; Wang X; Pang Y; Jiang C
    Protein Cell; 2021 May; 12(5):360-373. PubMed ID: 33346905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women with type 1 diabetes exhibit a progressive increase in gut Saccharomyces cerevisiae in pregnancy associated with evidence of gut inflammation.
    Bandala-Sanchez E; Roth-Schulze AJ; Oakey H; Penno MAS; Bediaga NG; Naselli G; Ngui KM; Smith AD; Huang D; Zozaya-Valdes E; Thomson RL; Brown JD; Vuillermin PJ; Barry SC; Craig ME; Rawlinson WD; Davis EA; Harris M; Soldatos G; Colman PG; Wentworth JM; Haynes A; Morahan G; Sinnott RO; Papenfuss AT; Couper JJ; Harrison LC;
    Diabetes Res Clin Pract; 2022 Feb; 184():109189. PubMed ID: 35051423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut mycobiome alterations and implications for liver diseases.
    Zeng S; Schnabl B
    PLoS Pathog; 2024 Aug; 20(8):e1012377. PubMed ID: 39116092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Gut Mycobiome Characterization of Gestational Diabetes Mellitus and Its Association With Dietary Intervention.
    Wu N; Mo H; Mu Q; Liu P; Liu G; Yu W
    Front Microbiol; 2022; 13():892859. PubMed ID: 35783435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
    Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
    Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fungal infections and the fungal microbiome in hepatobiliary disorders.
    Hartmann P; Schnabl B
    J Hepatol; 2023 Apr; 78(4):836-851. PubMed ID: 36565724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The intestinal mycobiome as a determinant of host immune and metabolic health.
    Gutierrez MW; Arrieta MC
    Curr Opin Microbiol; 2021 Aug; 62():8-13. PubMed ID: 33993019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
    Yang YJ; Ni YH
    J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered gut mycobiome in patients with end-stage renal disease and its correlations with serum and fecal metabolomes.
    Ren Y; Chen L; Guo R; Ma S; Li S; Zhang Y; Jiang H; Shi H; Zhang P
    J Transl Med; 2024 Feb; 22(1):202. PubMed ID: 38403655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mechanism of berberine alleviating metabolic disorder based on gut microbiome.
    Wang H; Zhang H; Gao Z; Zhang Q; Gu C
    Front Cell Infect Microbiol; 2022; 12():854885. PubMed ID: 36093200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics.
    Li D; Li Y; Yang S; Lu J; Jin X; Wu M
    Biomed Pharmacother; 2022 Sep; 153():113290. PubMed ID: 35724509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.